Short answer
HARROW, INC. (HROW) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights.
HARROW, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights
- Closing cash consideration fixed at $30.0 million, eliminating net working capital adjustment uncertainty
- Contingent milestone payments and other principal deal terms materially unchanged
- Japan rights exclusion may limit Harrow’s future geographic revenue opportunity for TYRVAYA
Item 2.01 · Completion of Acquisition or Disposition of Assets
- TYRVAYA rights acquired globally excluding Japan, including regulatory approvals, intellectual property, technology, inventory and contracts
- $30.0 million upfront cash payment, funded from cash on hand, reducing liquidity
- Up to $70.0 million additional contingent milestones tied to net-sales thresholds through December 31, 2029
- Japan opportunity retained through tiered royalties and planned collaboration with Viatris
- Acquisition closed October 1, 2026, adding TYRVAYA commercialization obligations and potential revenue upside
Item 7.01 · Regulation FD Disclosure
- Harrow completed its acquisition of the Acquired Assets on October 5, 2026
- Exhibit 99.1 contains the acquisition announcement and transaction details for investor review
Item EX-99.1 · Exhibit EX-99.1
- TYRVAYA acquisition closed for $30 million cash, with up to $70 million sales-based milestones, potential consideration $100 million
- Worldwide rights acquired except Japan, with Viatris retaining Japan commercialization and paying Harrow royalties
- TYRVAYA expected to contribute more than $30 million revenue in 2027
- Approximately 40 Viatris personnel joining in Q4 2026, expanding Harrow’s ocular-surface commercial capacity
- Portfolio now combines TYRVAYA and VEVYE, creating cross-selling and shared infrastructure opportunities in dry eye disease
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HARROW, INC. 8-K filings
Get the next HROW 8-K as it lands
Follow HROW for push alerts, or ask the research agent what this filing means.